Frank Ahmann, co-founder, President & CEO of XM Therapeutics, is an entrepreneur and executive with 30 years of experience in the biotech and medical device industries. He combines strategic vision and analysis with substantial operational experience in developing new technologies and startups. From concept to clinical proof of efficacy and commercialization, Frank has led the development of products including permanent cardiac implants, heart failure drug candidates, vascular and endovascular prostheses, immunoadsorption devices, and stem cell collection and processing systems. He planned and grew five start-up companies and two divisions of a multinational life sciences company. He co-founded MateraCor, a 2020 Medtech Incubator company acquired by Bioventrix in 2021. Previously, he was COO and CEO at start-ups including LoneStar Heart, Symphony Medical, Chimeric Therapies, and Allvivo. Frank also held senior management positions at Baxter International’s Biotech Group and Cardiovascular Group (now Edwards LifeSciences). He is a native Spanish, German, and English speaker with strong ties to the European medical market. He holds a BBA with Honors from the University of Texas at Austin and an MBA from Columbia University Graduate School of Business in New York City.
